By Dan Stanton
The pace of recruitment is the biggest challenge in carrying out trials in Eastern Europe, says Mabion which has extended an agreement with local CRO Altiora for its biosimilar study.
Mabion obtains permission from Croatia, Bosnia and Herzegovina, Serbia & Poland authorities to begin trial in lymphoma patients
Mabion SA, a leading biotechnological Polish company, announced that the company has obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma.
Mabion has permission to study patients with lymphoma in Croatia, Bosnia and Herzegovina, Serbia and Poland
By FirstWord Pharma
Mabion SA - Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies - obtained the consent of appropriate regulatory authorities in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform the clinical trial in patients with Diffuse Large B-cell Lymphoma.
Christian Homsy, MD; Celyad S.A.
During our business relationship, Altiora staff presented high professionalism, agility and above all devotion in every day conduct of business. We have also witnessed tremendous work that Altiora staff invested in supporting sites in all aspects of clinical trial, and all that returned in highest recruitment rates. As added value, Altiora have been of most help in handling difficult situations and giving valuable input based on their previous experience.
We have been collaborating with ever more competent employees, and Altiora management have promptly reacted in situations that warranted particular attention for diverse matters. Altiora staff were flexible on many occasions, building confidence in their know-how and willingness to keep business client even in very volatile clinical trials environment. Therefore I confirm that Altiora has proven as the most reliable partner.”
By Christian Homsy, MD; Chief Executive Officer, Celyad S.A.